{"id":936940,"date":"2026-02-13T09:25:28","date_gmt":"2026-02-13T14:25:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/"},"modified":"2026-02-13T09:25:28","modified_gmt":"2026-02-13T14:25:28","slug":"advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/","title":{"rendered":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Tainan, Taiwan, Feb.  13, 2026  (GLOBE NEWSWIRE) &#8212; Advanced Biomed Inc. (Nasdaq: ADVB) (the \u201cCompany\u201d, \u201cAdvanced Biomed\u201d), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the \u201cAgreement\u201d) with Chi\u2011Mei Medical Center to initiate a 120\u2011case feasibility study designed to evaluate the predictive accuracy of the Company\u2019s A+PerfusC<sup>\u2122<\/sup>, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro.<\/p>\n<p align=\"justify\">The feasibility study is a non\u2011interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi\u2011Mei Medical Center, with interim comparative data expected in May\u2013June 2026 and full study completion targeted by year\u2011end 2026. The study will compare ex\u2011vivo drug sensitivity results generated by the A+PerfusC platform from circulating tumor cells obtained via liquid biopsy with actual patient clinical outcomes to assess correlation and predictive performance. It follows the Company\u2019s September 2025 commercial launch of the A+PerfusC integrated perfusion 3D cell culture platform and represents an additional avenue to convert the system\u2019s laboratory strengths into evidence that can be used in clinical practice.<\/p>\n<p align=\"justify\">This collaboration is significant because it seeks to address a central limitation of current preclinical and guideline\u2011driven approaches to oncology treatment selection. Two\u2011dimensional cell culture models and xenograft animal models frequently fail to recapitulate the complex, patient\u2011specific biology of human tumors and are constrained by low throughput and long turnaround times. By contrast, the A+PerfusC platform isolates high\u2011viability circulating tumor cells using label\u2011free microfluidic technology and grows them in automated 3D culture arrays that enable parallel testing of multiple drugs and combinations. This functional, patient-derived testing approach aims to shorten the time to an evidence\u2011based treatment decision, reduce exposure to ineffective therapies and their toxicities, and provide clinicians with a practical tool to prioritize therapies most likely to benefit an individual patient.<\/p>\n<p align=\"justify\">Beyond direct patient impact, the platform also addresses practical and ethical constraints associated with animal\u2011based models. Replacing large cohorts of mice with high\u2011density arrays of patient\u2011derived tumor spheroids enables high\u2011throughput screening that is not feasible with xenografts, while Advanced Biomed\u2019s automated A+PerfusC<sup>TM<\/sup> system is intended to reduce labor intensity and scale functional testing to clinically actionable timeframes. The Company expects the feasibility study\u2019s results to inform the design of subsequent, larger clinical validation studies and to support its use as a predictive tool for treatment response and Clinical Decision Support (CDS), pending favorable outcomes and regulatory review.<\/p>\n<p align=\"justify\">\u201cWe believe the A+PerfusC platform can materially improve how oncologists select therapies by delivering patient\u2011specific, functional drug sensitivity data derived from a minimally invasive liquid biopsy,\u201d said Dr. Yi Lu, Chief Executive Officer of Advanced Biomed. \u201cThis feasibility study with Chi\u2011Mei Medical Center is a critical step toward demonstrating the platform\u2019s real\u2011world predictive value and advancing precision oncology beyond genomic inference to functional, individualized testing.\u201d<\/p>\n<p align=\"justify\">Advanced Biomed and Chi\u2011Mei Medical Center will jointly conduct the non\u2011commercial clinical research and collaborate on subsequent commercial development. Under the Agreement, both parties will share rights to project-related intellectual property and research outcomes.<\/p>\n<p align=\"justify\">\n        <b>About Advanced Biomed Inc.\u00a0<\/b><br \/>\n        <br \/>Advanced Biomed Inc. is a Nevada corporation specializing in innovative biomedical technologies for cancer detection and precision medicine.<\/p>\n<p align=\"justify\">Operating through the subsidiary in Taiwan, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in Taiwan and plans for future global expansion.<\/p>\n<p align=\"justify\">For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qQqcQ6VId3inymDLa-WR3qIg-MS7N-ZZAE1K37-rxQLAJv3ZaX7rv00Bug9fp4OBuRqarNrbrmG3TCg7f1v1TBdfEJp_oDyzf_YdOB_ULuE=\" rel=\"nofollow\" target=\"_blank\"><u>www.advanbiomed.com<\/u><\/a><u>.<\/u><\/p>\n<p align=\"justify\">\n        <b>Forward\u2011Looking Statements\u00a0<\/b><br \/>\n        <br \/>This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as \u201cmay, \u201cwill, \u201cintend,\u201d \u201cshould,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201cestimate\u201d or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company&#8217;s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the documents filed with the United States Securities and Exchange Commission (the \u201cSEC\u201d). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company&#8217;s filings with the SEC, which are available for review at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nABdaoSuTje_41M5R7m57qJoNDgTc_9bA-3h5dwyvWPbf-Ay4Bkrq8dEFGsbpgDtDJeI_bOdF2m-VJyzsnGycg==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.<\/p>\n<p align=\"left\">\n        <b>For more information, please contact:<\/b><br \/>\n        <br \/>Advanced Biomed Inc.<br \/>Steven I-Fang Cheng<br \/>Email:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eQ4pwu3fQ4PaM32oVl8Tk34Y1P_YLW3buHygiGqYq2X83Gbor9xzTBcbWQnk7Lp1i10JxK0Avy-_Oc7tMJZHVLMXFW-sYECWMvPI9FiUdHKKjTuSLijcq_RXlPB5F7R0\" rel=\"nofollow\" target=\"_blank\"><u>info@advbiomedicine.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QmCIFIzIFX16OBhuyi0E37YPZ-Tj_THC4Lzyadk-u3dcT_XQvPLwNSYG698f7mX7fzQOnQDEy1N_hyBtR92Q2OiEt5XWfz9e5ksZJLPpnEaGPf-AR54FfHOwuex9Gl6B\" rel=\"nofollow\" target=\"_blank\"><u>invest@advbiomedicine.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjlmYzNjYzItNDZjOC00YjFiLWFmYzItMjcyODVlNDEzMWM2LTUwMDEzMzQzNC0yMDI2LTAyLTEzLWVu\/tiny\/Advanced-Biomed-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Advanced Biomed Inc. (Nasdaq: ADVB) (the \u201cCompany\u201d, \u201cAdvanced Biomed\u201d), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the \u201cAgreement\u201d) with Chi\u2011Mei Medical Center to initiate a 120\u2011case feasibility study designed to evaluate the predictive accuracy of the Company\u2019s A+PerfusC\u2122, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non\u2011interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi\u2011Mei Medical Center, with interim comparative data expected in May\u2013June 2026 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-936940","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Advanced Biomed Inc. (Nasdaq: ADVB) (the \u201cCompany\u201d, \u201cAdvanced Biomed\u201d), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the \u201cAgreement\u201d) with Chi\u2011Mei Medical Center to initiate a 120\u2011case feasibility study designed to evaluate the predictive accuracy of the Company\u2019s A+PerfusC\u2122, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non\u2011interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi\u2011Mei Medical Center, with interim comparative data expected in May\u2013June 2026 &hellip; Continue reading &quot;Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T14:25:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery\",\"datePublished\":\"2026-02-13T14:25:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/\"},\"wordCount\":875,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/\",\"name\":\"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\",\"datePublished\":\"2026-02-13T14:25:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/","og_locale":"en_US","og_type":"article","og_title":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk","og_description":"Tainan, Taiwan, Feb. 13, 2026 (GLOBE NEWSWIRE) &#8212; Advanced Biomed Inc. (Nasdaq: ADVB) (the \u201cCompany\u201d, \u201cAdvanced Biomed\u201d), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the Company has entered into a clinical research collaboration agreement (the \u201cAgreement\u201d) with Chi\u2011Mei Medical Center to initiate a 120\u2011case feasibility study designed to evaluate the predictive accuracy of the Company\u2019s A+PerfusC\u2122, a perfusion-based 3D cell culture in a compact incubator designed to replicate human physiological conditions in vitro. The feasibility study is a non\u2011interventional clinical research project that received Institutional Review Board approval. Case collection has begun in early February 2026 at Chi\u2011Mei Medical Center, with interim comparative data expected in May\u2013June 2026 &hellip; Continue reading \"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-13T14:25:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery","datePublished":"2026-02-13T14:25:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/"},"wordCount":875,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/","name":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==","datePublished":"2026-02-13T14:25:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NDM5NSM3NDI1MjM1IzUwMDEzMzQzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/advanced-biomed-inc-announces-120-case-feasibility-study-with-chi-mei-medical-center-to-validate-aperfusc-integrated-perfusion-3d-cell-culture-platform-for-precisi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Advanced Biomed Inc. Announces 120\u2011Case Feasibility Study with Chi\u2011Mei Medical Center to Validate A+PerfusC\u2122 \u2013 Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=936940"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/936940\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=936940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=936940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=936940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}